Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Executive Summary

• Revive Therapeutics announced an update on its ongoing study of Bucillamine as a potential treatment for nerve‑agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC).
• The study remains active; final results will be released only after DRDC’s authorization.
• Revive reaffirmed its broader pipeline focus on infectious disease, medical countermeasures, psilocybin, and molecular hydrogen therapeutics.

Key Details

• Collaboration: Study performed jointly with DRDC, a Canadian Department of National Defence agency providing expertise and infrastructure for medical‑countermeasure development.
• Compound Evaluated: Bucillamine is being assessed for its ability to mitigate nerve‑agent–induced brain injury.
• Status: Research is ongoing; no efficacy or safety data have been disclosed at this time.
• Result Release: Final findings will be shared only with express authorization from DRDC.
• Future Updates: Revive committed to providing further updates as the study progresses toward completion.
• Pipeline Context: The company highlighted its pursuit of FDA regulatory incentives (EUA, Orphan Drug, Fast Track, Breakthrough Therapy) across multiple programs, including Bucillamine for nerve‑agent exposure and long COVID, plus psilocybin and molecular hydrogen therapeutics.

Notable Quotes

(No direct quotes were included in the release.)